clinical trial · NCT07428486
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center·phase1·not yet recruiting·n = 24
Phase IFLAG ChemotherapyLisaftoclaxPelcitoclaxRelapsed/RefractoryLymphoblastic Leukemia AcuteFludarabineCytarabineG-CSFLisaftoclaxPelcitoclax
brief summary
To find safe and effective doses of lisaftoclax and pelcitoclax in combination with FLAG chemotherapy in patients with relapsed/refractory T-ALL.
started
Aug 17, 2026
primary completion
Jun 12, 2030
completion
Jun 12, 2032
last updated
Feb 23, 2026
detailed description
Primary Objectives
• To establish the minimum safe and biologically-effective doses of lisaftoclax and pelcitoclax in combination with FLAG chemotherapy
Secondary Objectives
* To determine the CR/CRi rate of the combination regimen * To assess other efficacy endpoints (CR rate, measurable residual disease negativity by flow cytometry and clonoSEQ, relapse-free survival, overall survival, event-free survival) * To determine the safety of the combination regimen
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol